Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia

Frontiers in Molecular Neuroscience

Volumn 1, Issue APR, 2008, Pages

  Kehrer, Colin ^a   Maziashvili, Nino ^a   Dugladze, Tamar ^a   Gloveli, Tengis ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gamma rhythm; Interneurons; Network oscillations; NMDA hypofunction; Phencyclidine

Indexed keywords

EID: 67749088757     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/neuro.02/006.2008     Document Type: Article

References (143)

1. Abdul-Monim, Z., Reynolds, G. P., and Neill, J. C. (2003). The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J. Psychopharmacol. 17, 57-65.
2. Adams, B., and Moghaddam, B. (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci. 18, 5545-5554.
3. Akbarian, S., Sucher, N. J., Bradley, D., Tafazzoli, A, Trinh, D., Hetrick, W. P., Potkin, S. G., Sandman, C. A., Bunney, W. E. Jr, and Jones, E. G. (1996). Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrencs. Neuroscience 16, 19-30.
4. Anden, N. E., Butcher, S. G., Corrodi, H., Fuxe, K., and Ungerstedt, U. (1970). Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur. J. Pharmacol. 11, 303-314.
5. Averbeck, B. B., and Lee, D. (2004). Coding and transmission of information by neural ensembles. Trends Neurosci. 27, 225-230.
6. Baldeweg, T., Spence, S., Hirsch, S. R., and Gruzelier, J. (1998). Gamma-band electroencephalographic oscillations in a patient with somatic hallucinations. Lancet 352, 620-621.
7. Ban, T. A., Guy, W., and Wilson, W. H. (1984). Description and distribution of the subtypes of chronic schizophrenia based on Leonhard's classification. Psychiatr. Dev. 2, 179-199.
8. Bartos, M., Vida, I., and Jonas P. (2007). Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat. Rev. Neurosci. 8, 45-56.
9. Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., and Dugan, L. L. (2007). Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 318, 1645-1647.
10. Benes, F. M. (1999). Evidence for altered trisynaptic circuitry in schizophrenic hippocampus. Biol. Psychiatry. 46, 589-599.
11. Bragin, A., Jandó, G., Nádasdy, Z., Hetke, J., Wise, K., and Buzsáki, G. (1995). Gamma (40-100 Hz) oscillation in the hippocampus of the behaving rat. J. Neurosci. 15, 47-60.
12. Braun, I., Genius, J., Grunze, H., Bender, A., Möller, H. J., and Rujescu, D. (2007). Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. Schizophr. Res. 97, 254-263.
13. Bucci, P., Mucci, A., Merlotti, E., Volpe, U., and Galderisi, S. (2007). Induced gamma activity and event-related coherence in schizophrenia. Clin. EEG Neurosci. 38, 96-104.
14. Buzsáki, G. (2002). Theta oscillations in the hippocampus. Neuron 33, 325-340.
15. Buzsáki, G., and Draguhn, A. (2004). Neuronal oscillations in cortical networks. Science 304, 1926-1929.
16. Carlsson, A. (1988). The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1, 179-186.
17. Carlsson, A., Waters, N., and Carlsson, M. L. (1999). Neurotransmitter interactions in schizophrenia-therapeutic implications. Eur. Arch. Psychiatry Clin. Neurosci. 249, 37-43.
18. Cho, R. Y., Konecky, R. O., and Carter, C.S. (2006). Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 103, 19878-19883.
19. Clementz, B. A., Dzau, J. R., Blumenfeld, L. D., Matthews, S., and Kissler, J. (2003). Ear of stimulation determines schizophrenia-normal brain activity differences in an auditory paired-stimuli paradigm. Eur. J. Neurosci. 18, 2853-2858.
20. Corso, T. D., Sesma, M. A., Tenkova, T. I., Der, T. C., Wozniak, D. F., Farber, N. B., and Olney, J. W. (1997). Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res. 752, 1-14.
21. Coyle, J. T. (2004). The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochem. Pharmacol. 68, 1507-1514.
22. Coyle, J. T. (2006). Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 26, 365-384.
23. Csicsvari, J., Jamieson, B., Wise, K. D., and Buzsáki, G. (2003). Mechanisms of gamma oscillations in the hippocampus of the behaving rat. Neuron 37, 311-322.
24. Cunningham, M. O., Hunt, J., Middleton, S., LeBeau, F. E., Gillies, M. J., Davies, C. H., Maycox, P. R., Whittington, M. A., and Racca, C. (2006). Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J. Neurosci. 26, 2767-2776.
25. Deakin, J. F., and Simpson, M. D. (1997). A two-process theory of schizophrenia: evidence from studies in post-mortem brain. J. Psychiatr. Res. 31, 277-295.
26. Dean, B. (2001). A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia. Clin. Exp. Pharmacol. Physiol. 28, 74-78.
27. Dracheva, S., Marras, S. A., Elhakem, S. L., Kramer, F. R., Davis, K. L., and Haroutunian, V. (2001). N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am. J. Psychiatry 158, 1400-1410.
28. Dugladze, T., Lepsveridze, E., Breustedt, J., Kehrer, C., Heinemann, U., and Gloveli, T. (2004). Effects of phencyclidines on signal transfer from the entorhinal cortex to the hippocampus in rats. Neurosci. Lett. 354, 185-188.
29. Dugladze, T., Vida, I., Tort, A. B., Gross, A., Otahal, J., Heinemann, U., Kopell, N. J., and Gloveli, T. (2007). Impaired hippocampal rhythmogenesis in a mouse model of mesial temporal lobe epilepsy. Proc. Natl. Acad. Sci. U.S.A. 104, 17530-17535.
30. Eisener, A., Pato, M. T., Medeiros, H., Carvalho, C., and Pato, C. N. (2007). Genetics of schizophrenia: recent advances. Psychopharmacol. Bull. 40, 168-177.
31. Ellison, G. (1994). Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport 5, 2688-2692.
32. Ellison, G., and Switzer, R. C. (1993). Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport 5, 17-20.
33. Enomoto, T., Noda, Y., and Nabeshima, T. (2007). Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find. Exp. Clin. Pharmacol. 29, 291-301.
34. Fisahn, A., Pike, F. G., Buhl, E. H., and Paulsen, O. (1998). Cholinergic induction of network oscillations at 40 Hz in the hippocampus in vitro. Nature 394, 186-189.
35. Flores, C., and Coyle, J. T. (2003). Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. Neuropsychopharmacology 28, 1227-1234.
36. Freund, T. F., and Buzsaki, G. (1996). Interneurons of the hippocampus. Hippocampus 6, 347-470.
37. Ford, J. M., Krystal, J. H., and Mathalon, D. H. (2007). Neural synchrony in schizophrenia: from networks to new treatments. Schizophr. Bull. 33, 848-852.
38. Gao, X. M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B., and Tamminga, C. A. (2000). Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatry 157, 1141-1149.
39. Gloveli, T., Dugladze, T., Saha, S., Monyer, H., Heinemann, U., Traub, R. D., Whittington, M. A., and Buhl, E. H. (2005a). Differential involvement of oriens/pyramidale interneurones in hippocampal network oscillations in vitro. J. Physiol. 562, 131-147.
40. Gloveli, T., Dugladze, T., Rotstein, H. G., Traub, R. D., Monyer, H., Heinemann, U., Whittington, M. A., and Kopell, N. J. (2005b). Orthogonal arrangement of rhythmgenerating microcircuits in the hippocampus. Proc. Natl. Acad. Sci. U.S.A. 102, 13295-13300.
41. Gloveli, T., Iserhot, C., Schmitz, D., Castrén, E., Behr, J., and Heinemann, U. (1997). Systemic administration of the phencyclidine compound MK-801 affects stimulus-induced field potentials selectively in layer III of rat medial entorhinal cortex. Neurosci. Lett. 221, 93-96.
42. Gonzalez-Burgos, G., Hashimoto, T., and Lewis, D. A. (2007). Inhibition and timing in cortical neural circuits. Am. J. Psychiatry 164, 12.
43. Grace, A. A. (1991). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41, 1-24.
44. Granger, B. (1997). Synaptogenesis, synaptic pruning and schizophrenias. Eur. Psychiatry 12, 175-178.
45. Guilarte, T. R., Hammoud, D. A., McGlothan, J. L., Caffo, B. S., Foss, C. A., Kozikowski, A. P., and Pomper, M. G. (2008). Dysregulation of glutamate carboxypeptidase II in psychiatric disease. Schizophr. Res. 99, 324-332.
46. Harrison, P. J., Law, A. J., and Eastwood, S. L. (2003). Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann. N. Y. Acad. Sci. 1003, 94-101.
47. Harrison, P. J., and Owen, M. J. (2003). Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361, 417-419.
48. Hashimoto, T., Nishino, N., Nakai, H., and Tanaka, C. (1991). Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 48, 355-363.
49. Heckers, S., Stone, D., Walsh, J., Shick, J., Koul, P., and Benes, F. M. (2002). Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch. Gen. Psychiatry 59, 521-529.
50. Herrmann, C. S., and Demiralp, T. (2005). Human EEG gamma oscillations in neuropsychiatric disorders. Clin. Neurophysiol. 116, 2719-2733.
51. Hiramatsu, M., Cho, A. K., and Nabeshima, T. (1989). Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur. J. Pharmacol. 166, 359-366.
52. Homayoun, H., and Moghaddam, B. (2007). NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27, 11496-11500.
53. Howard, A., Tamas, G., and Soltesz, I. (2005). Lighting the chandelier: new vistas for axo-axonic cells. Trends Neurosci. 28, 310-316.
54. Idris, N. F., Repeto, P., Neill, J. C., and Large, C. H. (2005). Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology 179, 336-348.
55. Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vockler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., and Olney, J. W. (1999). Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283, 70-74.
56. Ikonomidou, C., Mosinger, J. L., Salles, K. S., Labruyere, J., and Olney, J. W. (1989). Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity. J. Neurosci. 9, 2809-2818.
57. Javitt, D. C., and Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308.
58. Jensen, O., Kaiser, J., and Lachaux, J. P. (2007). Human gamma-frequency oscillations associated with attention and memory. Trends Neurosci. 30, 317-324.
59. Jentsch, J. D., Dazzi, L., Chhatwal, J. P., Verrico, C. D., and Roth, R. H. (1998). Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats. Neurosci. Lett. 258, 175-178.
60. Jentsch, J. D., and Roth, R. H. (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201-225.
61. Jones, R. S., and Buhl, E. H. (1993). Basket-like interneurones in layer II of the entorhinal cortex exhibit a powerful NMDA-mediated synaptic excitation. Neurosci. Lett. 149, 35-39.
62. Jones, H., Curtis, V. A., Wright, P., and Lucey, J. V. (1998). Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms. Am. J. Psychiatry 155, 838-840.
63. Kaiser, S., Foltz, L. A., George, C. A., Kirkwood, S. C., Bemis, K. G., Lin, X., Gelbert, L. M., and Nisenbaum, L. K. (2004). Phencyclidine-induced changes in rat cortical gene expression identified by microarray analysis: implications for schizophrenia. Neurobiol. Dis. 16, 220-235.
64. Kalkman, H. O., and Loetscher, E. (2003). GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic-and glutamatergic theories of psychosis. J. Neural Transm. 10, 803-812.
65. Kehrer, C., Dugladze, T., Maziashvili, N., Wójtowicz, A., Schmitz, D., Heinemann, U., and Gloveli, T. (2007). Increased inhibitory input to CA1 pyramidal cells alters hippocampal gamma frequency oscillations in the MK-801 model of acute psychosis. Neurobiol. Dis. 25, 545-552.
66. Keilhoff, G., Becker, A., Grecksch, G., Wolf, G., and Bernstein, H. G. (2004). Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience 126, 591-598.
67. Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., and Holzmüller, B. (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20, 379-382.
68. Kim, S. H., Price, M. T., Olney, J. W., and Farber, N. B. (1999). Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-adrenergic agonists. Mol. Psychiatry 4, 344-352.
69. Kirkpatrick, B., Buchanan, R. W., Ross, D. E., and Carpenter, W. T. Jr (2001). A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry 58, 165-171.
70. Kitaichi, K., Yamada, K., Hasegawa, T., Furukawa, H., and Nabeshima, T. (1994). Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin. Jpn. J. Pharmacol. 66, 181-189.
71. Kitaichi, K., Yamada, K., Yoneda, Y., Ogita, K., Hasegawa, T., Furukawa, H., and Nabeshima, T. (1995). Risperidone prevents the development of supersensitivity, but not tolerance, to phencyclidine in rats treated with subacute phencyclidine. Life Sci. 56, 531-543.
72. Knable, M. B., Hyde, T. M., Herman, M. M., Carter, J. M., Bigelow, L., and Kleinman, J. E. (1994). Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol. Psychiatry 36, 827-835.
73. Konradi, C., and Heckers, S. (2001). Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol. Psychiatry 50, 729-742.
74. Kopell, N., Pervouchine, D., Rotstein, H., Netoff, T., Whittington, M. A., and Gloveli, T. (2007). Multiple rhythms and switches in the nervous system. In: Frontiers of Applied Mathematics, D.Y. Hsieh, M. Zhang and W. Sun, eds (Beijing, China, World Scientific), pp. 1-17.
75. Krystal, J. H., Seibyl, J. P., Price, L. H., Woods, S. W., Heninge, G. R., Aghajanian, G. K., and Charney, D. S. (1993). m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch. Gen. Psychiatry 50, 624-635.
76. Kwon, J. S., O'Donnell, B. F., Wallenstein, G. V., Greene, R. W., Hirayasu, Y., Nestor, P. G., Hasselmo, M. E., Potts, G. F., Shenton, M. E., and McCarley, R. W. (1999). Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch. Gen. Psychiatry 56, 1001-1005.
77. Lahti, A. C., Koffel, B., LaPorte, D., and Tamminga, C. A. (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13, 9-19.
78. Laurent, G., and Davidowitz, H. (1994). Encoding of olfactory information with oscillating neural assemblies. Science 265, 1872-1875.
79. Lee, K. H., Williams, L. M., Breakspear, M., and Gordon, E. (2003a). Synchronous gamma activity: a review and contribution to an integrative neuroscience model of schizophrenia. Brain Res. Brain Res. Rev. 41, 57-78.
80. Lee, K. H., Williams, L. M., Haig, A., Goldberg, E., and Gordon, E. (2001). An integration of 40 Hz Gamma and phasic arousal: novelty and routinization processing in schizophrenia. Clin. Neurophysiol. 112, 1499-1507.
81. Lee, K. H., Williams, L. M., Haig, A., and Gordon, E. (2003b). "Gamma (40 Hz) phase synchronicity" and symptom dimensions in schizophrenia. Cognit. Neuropsychiatry 8, 57-71.
82. Lewis, D. A., Hashimoto, T., and Volk, D. W. (2005). Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6, 312-324.
83. Lewis, D. A., and Moghaddam, B. (2006). Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch. Neurol. 63, 1372-1376.
84. Llinás, R. R., Ribary, U., Jeanmonod, D., Kronberg, E., and Mitra, P. P. (1999). Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography. Proc. Natl. Acad. Sci. U.S.A. 96, 15222-15227.
85. Lodge, D., and Anis, N. A. (1982). Effects of phencyclidine on excitatory amino acid activation of spinal interneurones in the cat. Eur. J. Pharmacol. 77, 203-204.
86. Loring, D. W., and Largen, J. W. (1985). Neuropsychological patterns of presenile and senile dementia of the Alzheimer type. Neuropsychologia 23, 351-357.
87. Loscher, W., Annies, R., and Honack, D. (1991). The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci. Lett. 128, 191-194.
88. Luby, E. D., Cohen, B. D., Rosenbaum, F., Gottlieb, J., and Kelley, R. (1959). Study of a new schizophrenomimetic drug, Sernyl. A. M. A. Arch. Neurol. Psychiatry 81, 363-369.
89. Ma, J., and Leung, L. S. (2000). Relation between hippocampal gamma waves and behavioral disturbances induced by phencyclidine and methamphetamine. Behav. Brain Res. 111, 1-11.
90. Mann, E. O., Radcliffe, C. A., and Paulsen, O. (2005). Hippocampal gamma-frequency oscillations: from interneurones to pyramidal cells, and back. J. Physiol. 562, 55-63.
91. McBain, C. J., and Dingledine, R. (1993). Heterogeneity of synaptic glutamate receptors on CA3 stratum radiatum interneurones of rat hippocampus. J. Physiol. 462, 373-392.
92. McBain, C. J., and Fisahn, A. (2001). Interneurones unbound. Nat. Rev. Neurosci. 2, 11-23.
93. Meyer, A. H., Katona, I., Blatow, M., Rozov, A., and Monyer H. (2002). In vivo labeling of parvalbumin-positive interneurons and analysis of electrical coupling in identified neurons. J. Neurosci. 22, 7055-7064.
94. Miles, R., Toth, K., Gulyas, A. I., Hajos, N., and Freund, T. F. (1996). Differences between somatic and dendritic inhibition in the hippocampus. Neuron 16, 815-823.
95. Mita, T., Hanada, S., Nishino, N., Kuno, T., Nakai, H., Yamodori, T., Mizoi, Y., and Tanaka, C. (1986). Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol. Psychiatry 21, 1407-1414.
96. Moghaddam, B., Adams, B., Verma, A., and Daly, D. (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921-2927.
97. Moore, H., West, A. R., and Grace, A. A. (1999). The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biol. Psychiatry 46, 40-55.
98. Morris, B. J., Cochran, S. M., and Pratt, J. A. (2005). PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5, 101-106.
99. Morris, H. M., Hashimoto, T., and Lewis, D. A. (2008). Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb. Cortex [Epub ahead of print].
100. Mouri, A., Noda, Y., Enomoto, T., and Nabeshima, T. (2007). Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem. Int. 51, 173-184.
101. Murai, R., Noda, Y., Matsui, K., Kamei, H., Mouri, A., Matsuba, K., Nitta, A., Furukawa, H., and Nabeshima, T. (2007). Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling. Behav. Brain Res. 180, 152-160.
102. Murthy, V. N., and Fetz, E. E. (1996). Oscillatory activity in sensorimotor cortex of awake monkeys: synchronization of local field potentials and relation to behavior. J. Neurophysiol. 76, 3949-3967.
103. Nabeshima, T., Yamada, K., Yamaguchi, K., Hiramatsu, M., Furukawa, H., and Kameyama, T. (1983). Effect of lesions in the striatum, nucleus accumbens and medial raphe on phencyclidine-induced stereotyped behaviors and hyperactivity in rats. Eur. J. Pharmacol. 91, 455-462.
104. Nagai, T., Noda, Y., Une, T., Furukawa, K., Furukawa, H., Kan, Q. M., and Nabeshima, T. (2003). Effect of AD-5423 on animal models of schizophrenia: phencyclidineinduced behavioral changes in mice. Neuroreport 14, 269-272.
105. Noda, Y., Mamiya, T., Furukawa, H., and Nabeshima, T. (1997). Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur. J. Pharmacol. 324, 135-140.
106. Noda, Y., Yamada, K., Furukawa, H., and Nabeshima, T. (1995). Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br. J. Pharmacol. 116, 2531-2537.
107. Nyíri, G., Stephenson, F. A., Freund, T. F., and Somogyi, P. (2003). Large variability in synaptic N-methyl-D-aspartate receptor density on interneurons and a comparison with pyramidal-cell spines in the rat hippocampus. Neuroscience 119, 347-363.
108. Ohrmann, P., Siegmund, A., Suslow, T., Pedersen, A., Spitzberg, K., Kersting, A., Rothermundt, M., Arolt, V., Heinde, W., and Pfleiderer, B. (2007). Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J. Psychiatr. Res. 41, 625-634.
109. Oliva, A. A. Jr, Jiang, M., Lam, T., Smith, K. L., and Swann, J. W. (2000). Novel hippocampal interneuronal subtypes identified using transgenic mice that express green fluorescent protein in GABAergic interneurons. J. Neurosci. 20, 3354-3368.
110. Olney, J. W., and Farber, N. B. (1995). Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52, 998-1007.
111. Olney, J. W., Labruyere, J., and Price, M. T. (1989). Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244, 1360-1362.
112. Olney, J. W., Newcomer, J. W., and Farber, N. B. (1999). NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33, 523-533.
113. Pearlson, G. D. (2000). Neurobiology of schizophrenia. Ann. Neurol. 48, 556-566.
114. Pinault, D. (2008). N-Methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex. Biol. Psychiatry 63, 730-735.
115. Politoff, A. L., Monson, N., Stadter, R. P., and Hass, P. (1995). Severity of dementia correlates with loss of broad-band visual cortical responses. Dementia 6, 169-173.
116. Politoff, A. L., Stadter, R. P., Monson, N., and Hass, P. (1996). Cognition-related EEG abnormalities in nondemented Down syndrome subjects. Dementia 7, 69-75.
117. Qiao, H., Noda, Y., Kamei, H., Nagai, T., Furukawa, H., Miura, H., Kayukawa, Y., Ohta, T., and Nabeshima, T. (2001). Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 12, 11-15.
118. Roberts, E. (1972). Prospects for research on schizophrenia. An hypotheses suggesting that there is a defect in the GABA system in schizophrenia. Neurosci. Res. Program Bull. 10, 468-482.
119. Roelfsema, P. R. (1998). Solutions for the binding problem. Z. Naturforsch., C, Biosci. 53, 691-715.
120. Rossler, W., Salize, H. J., van Os, J., and Riecher-Rossler, A. (2005). Size of burden of schizophrenia and psychiatric disorders. Eur. Neuropsychopharmacol. 15, 399-409.
121. Rujescu, D., Bender, A., Keck, M., Hartmann, A. M., Ohl, F., Raeder, H., Giegling, I., Genius, J., McCarley, R. W., Möller, H. J., and Grunze, H. (2006). Pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol. Psychiatry 59, 721-729.
122. Sakai, T., Oshima, A., Nozaki, Y., Ida, I., Haga, C., Akiyama, H., Nakazato, Y., and Mikuni, M. (2008). Changes in density of calcium-binding-protein-immunoreactive GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder. Neuropathology 28, 143-150.
123. Sams-Dodd, F. (1995). Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment. J. Neurosci. Methods 59, 157-167.
124. Sams-Dodd, F. (1996). Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 7, 3-23.
125. Sesack, S. R., Carr, D. B., Omelchenko, N., and Pinto, A. (2003). Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann. N. Y. Acad. Sci. 1003, 36-52.
126. Singer, W. (2001). Consciousness and the binding problem. Ann. N. Y. Acad. Sci. 929, 123-146.
127. Singer, W., and Gray, C. M. (1995). Visual feature integration and the temporal correlation hypothesis. Annu. Rev. Neurosci. 18, 555-586.
128. Slewa-Younan, S., Gordon, E., Williams, L., Haig, A. R., and Goldberg, E. (2001). Sex differences, gamma activity and schizophrenia. Int. J. Neurosci. 107, 131-144.
129. Somogyi, P., and Klausberger, T. (2005). Defined types of cortical interneurone structure space and spike timing in the hippocampus. J. Physiol. 562, 9-26.
130. Spencer, K. M., Nestor, P. G., Perlmutter, R., Niznikiewicz, M. A., Klump, M. C., Frumin, M., Shenton, M. E., and McCarley, R. W. (2004). Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 101, 17288-17293.
131. Spencer, K. M., Niznikiewicz, M. A., Shenton, M. E., and McCarley, R. W. (2008). Sensoryevoked gamma oscillations in chronic schizophrenia. Biol. Psychiatry 63, 744-747.
132. Szabadics, J., Varga, C., Molnár, G., Oláh, S., Barzó, P., and Tamás, G. (2006). Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits. Science 311, 233-235.
133. Tan, H. Y., Callicott, J. H., and Weinberger, D. R. (2007). Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb. Cortex 17, 71-81.
134. Thompson, J. L., Pogue-Geile, M. F., and Grace, A. A. (2004). Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms. Schizophr. Bull. 30, 875-900.
135. Tort, A. B., Rotstein, H. G., Dugladze, T., Gloveli, T., and Kopell, N. J. (2007). On the formation of gamma-coherent cell assemblies by oriens lacunosum-moleculare interneurons in the hippocampus. Proc. Natl. Acad. Sci. U.S.A. 104, 13490-13495.
136. Wang, C. Z., Yang, S. F., Xia, Y., and Johnson, K. M. (2007). Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurons. Neuropsychopharmacology [Epub ahead of print].
137. Whittington, M. A., Traub, R. D., and Jefferys, J. G. (1995). Synchronized oscillations in interneuron networks driven by metabotropic glutamate receptor activation. Nature 373, 612-615.
138. Wozniak, D. F., Dikranian, K., Ishimaru, M. J., Nardi, A., Corso, T. D., Tenkova, T., Olney, J. W., and Fix, A. S. (1998). Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: potential relevance to Alzheimer's disease. Neurobiol. Dis. 5, 305-322.
139. Vaisanen, J., Linden, A. M., Lakso, M., Wong, G., Heinemann, U., and Castren, E. (1999). Excitatory actions of NMDA receptor antagonists in rat entorhinal cortex and cultured entorhinal cortical neurons. Neuropsychopharmacology 21, 137-146.
140. Vanderwolf, C. H. (1969). Hippocampal electrical activity and voluntary movement in the rat. Electroencephalogr. Clin. Neurophysiol. 26, 407-418.
141. van Elst, L. T., Valerius, G., Büchert, M., Thiel, T., Rüsch, N., Bubl, E., Hennig, J., Ebert, D., and Olbrich, H. M. (2005). Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol. Psychiatry 58, 724-730.
142. Yordanova, J., Banaschewski, T., Kolev, V., Woerner, W., and Rothenberger, A. (2001). Abnormal early stages of task stimulus processing in children with attention-deficit hyperactivity disorder-evidence from event-related gamma oscillations. Clin. Neurophysiol. 112, 1096-1098.
143. Yoshida, K., and Oka, H. (1995). Topographical projections from the medial septum-diagonal band complex to the hippocampus: a retrograde tracing study with multiple fluorescent dyes in rats. Neurosci. Res. 21, 199-209.